Clinical trial design for rare cancers: why a less conventional route may be required
نویسندگان
چکیده
منابع مشابه
Margaret McCartney: Why less confidence may be a good thing.
In any of the exams I’ve ever sat I’ve never been asked, “What don’t we know?” Hormone replacement therapy (HRT) is in the news. The papers say that GPs aren’t prescribing it enough. 2 Further, the National Institute for Health and Care Excellence has said that its new advice on menopause is “to help GPs and other healthcare professionals to be more confident in prescribing HRT and women more c...
متن کاملWhy Democracies May Actually Be Less Reliable Allies
Recent research builds on the observation that democracies have more durable alliances to argue that democracies make more reliable allies. This need not be the case. Alliances serve as commitment devices, adding ex ante credibility to states’ claims about ex post behavior. Variation in alliance durability must reflect differences in the desirability of formalizing alignments. Put simply, democ...
متن کاملAdipoRon may be benefit for atherosclerosis prevention
Atherosclerosis has serious role in coronary arteries disease,so it is important to establish effective strategies for prevention or even treatment of atherosclerosis. Adiponectin, as one of the most abundant adipokines, has insulin sensitivity, anti-inflammatory and anti-atherogenic properties. Disturbed adiponectin actions through its receptor, (AdipoR1 and AdipoR2) may be involved in atheros...
متن کاملA three-stage clinical trial design for rare disorders.
Many clinical trials of uncommon diseases are underpowered because of the difficulty of recruiting adequate numbers of subjects. We propose a clinical trial design with improved statistical power compared to the traditional randomized trial for use in clinical trials of rare diseases. The three-stage clinical trial design consists of an initial randomized placebo-controlled stage, a randomized ...
متن کاملClinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
BACKGROUND The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research. SETTINGS The International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the developmen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Clinical Pharmacology
سال: 2015
ISSN: 1751-2433,1751-2441
DOI: 10.1586/17512433.2015.1088382